Effects and prices of the Laotian version of Avatrombopag/Suxin

Lao version of Avatrombopag/Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA), mainly used to treat primary chronic immune thrombocytopenia (ITP) and other specific types of thrombocytopenia in adults. There are multiple Laotian versions of avatrombopag on the market in overseas markets, which fall into the category of generic drugs. Common manufacturers may include Laos Lucius Pharmaceuticals, ASEAN Pharmaceuticals, United Pharmaceuticals, etc. The drugs they produce are basically the same as the original drugs in terms of ingredients, but there may be slight differences in specifications, manufacturers or prices.

In terms of effects, the Lao version of avatrombopag stimulates the proliferation and differentiation of megakaryocytes in the bone marrow and promotes the production and maturation of platelets, thereby significantly increasing the platelet count. This mechanism of action makes avatrombopag excellent in the treatment of thrombocytopenia. Clinical trials have shown that avatrombopag can significantly increase patients' platelet counts, reduce the risk of bleeding, and improve patients' quality of life. ForITP patients, avatrombopag is an effective treatment option that can help patients restore normal platelet levels and reduce bleeding events caused by thrombocytopenia.

In addition, avatropopag is also commonly used to treat patients with chronic liver disease-related thrombocytopenia (CLD-PLT) during planned or surgical procedures. By increasing platelet levels, avatrombopag can reduce the risk of bleeding during surgery and ensure smooth operation.

The Laotian version of avatrombopag currently sold overseas is available in common specifications:20mg*15 tablets, 20mg*28 tablets, etc. The price per box is about more than 500 yuan (the price may fluctuate due to the exchange rate). This price provides more patients with an affordable treatment option.